PGM
CSTL icon

Parian Global Management’s Castle Biosciences CSTL Stock Holding History

Parian Global Management’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-29,498
Closed -$1.26M – 17
2021
Q4 		$1.26M Buy
+29,498
New +$1.54M 1.02% 26

Other funds holding CSTL

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
GPGA
Grandeur Peak Global Advisors Salt Lake City, Utah $427M AUM 39.14% 1-Year Est. Return

Parian Global Management's CSTL Position: Q1 2022 in Review

Parian Global Management sold out of Castle Biosciences (CSTL) in Q1 2022, closing a stake of 29,498 shares — an estimated $1.26M sold.

Parian Global Management first reported a position in CSTL in Q4 2021 and held it in 1 quarter. The position peaked at $1.26M in Q4 2021. 160 funds tracked by Wall St. Rank hold CSTL as of Q1 2022.

  • Parian Global Management reported no remaining Castle Biosciences position as of Q1 2022 after selling out during the quarter.
  • Parian Global Management sold 29,498 Castle Biosciences shares in Q1 2022, an estimated $1.26M.
  • Parian Global Management first reported a position in Castle Biosciences in Q4 2021 and held it in 1 quarter.
  • Parian Global Management's Castle Biosciences position peaked at $1.26M in Q4 2021.
  • 160 funds tracked by Wall St. Rank held Castle Biosciences as of Q1 2022.

Based on Parian Global Management's 13F filing for Q1 2022, filed 16 May 2022.